¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Screening, newborn hearing"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
¿µ¹® hearing test ÇÑ±Û Ã»·Â°Ë»ç
¼³¸í   
  ±Í°¡ µé¸®´Â Á¤µµ¸¦ ÃøÁ¤Çϴ °Ë»ç. Ã»°¢°Ë»ç¶ó°íµµ ÇÑ´Ù. ¼Ò¸®³ª ¸ñ¼Ò¸®°¡ Àß µé¸®´ÂÁöÀÇ ¿©ºÎ µî Ã»°¢ÀÇ ¿¹¹ÎÇÑ Á¤µµ¸¦ ÃøÁ¤Çϴ ÀÏÀÌ´Ù. °Ë»ç¿¡´Â Ã»·Â°è³ª ¼Ò¸®±Á¼è µîÀÇ ±â±¸¿¡ ÀÇÇØ¼­ ¾ò´Â À½¿ø, Áï ¼øÀ½À» »ç¿ëÇϸç, »ç¶÷ÀÇ ¸ñ¼Ò¸®³ª ½Ã°è¼Ò¸® µîµµ À½¿øÀ¸·Î »ç¿ëµÈ´Ù. ¶Ç À½ÆÄ°¡ ÀüÆÄµÇ´Â ¸ÅÁú¿¡ µû¶ó ±âµµ Ã»·Â°Ë»ç¿Í °ñµµ Ã»·Â°Ë»ç·Î ±¸º°µÇ±âµµ ÇÑ´Ù. °Ë»çÀÇ ³»¿ëÀ¸·Î´Â Ã»°¢ÀÇ »óÇÏÀ½°è³ª ÃÖ¼Ò °¡Ã»¹®ÅΰªÀÇ °Ë»ç¸¦ ºñ·ÔÇÏ¿©, ÃæºÐÈ÷ µé¸®´Â ¼Ò¸®¸¦ »ç¿ëÇÏ¿© ±×°ÍÀÌ µé¸®´Â »óŸ¦ Á¶»çÇϴ ¹®Åΰª°Ë»ç(¼Ò¸®ÀÇ Å©±â¿Í »óÅÂÀÇ °Ë»ç, ¼¼±âÀÇ ÆÇº°¿ª°Ë»ç µî) ¿Ü¿¡ À½ÇâÀÚ±ØÀÇ ¹ÝÀÀÀ¸·ÎºÎÅ͠Ÿ°¢ÀûÀ¸·Î Á¶»çÇϴ ¹æ¹ýµµ ÀÖÀ¸¸ç, À̰ÍÀº ÁַΠ°«³­¾Æ±â³ª Á¤½Åº´È¯ÀÚ¿¡ ´ëÇÏ¿© »ç¿ëµÈ´Ù. ÁַΠû·Â°è°¡ »ç¿ëµÇ°í, Ã»·ÂÀº µ¥½Ãº§(dB)·Î Ç¥½ÃµÈ´Ù. Á¤»óÀÎÀº 0dBÀ̰í, ³­Ã»ÀÚÀϼö·Ï ±× ¼ö°¡ Ä¿Áö¸ç, 60dBÀÌ»óÀº »ó´çÈ÷ ³­Ã»À̰í, 80dB ÀÌ»óÀ̸頱͸ӰŸ®ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • screening program
    Áý´Ü°ËÁø»ç¾÷, À¯¼Ò°ßÀڹ߰߻ç¾÷
  • screening test
    ¼±º°°Ë»ç
  • audiometric hearing loss
    û·Â¼Ò½Ç
  • air conduction hearing
    °ø±âÀüµµµè±â, °ø±âÀüµµÃ»·Â
  • absolute hearing
    Àý´ëÀ½°¨
  • binaural hearing
    ¾çÂʱ͵è±â, ¾çÀÌû
  • bone conduction hearing
    »ÀÀüµµµè±â, °ñÀüµµÃ»·Â
  • conductive hearing loss
    ÀüÀ½³­Ã», Àüµµ³­Ã»
  • congenital hereditary hearing loss
    ¼±ÃµÀ¯Àü³­Ã»
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • double disharmonic hearing
    ÀÌÁßµè±â, º¹Ã»
  • electric hearing aid
    Àü±âº¸Ã»±â
  • functional hearing loss
    ±â´É³­Ã»
  • familial progressive hearing loss
    °¡Á·¼ºÁøÇ೭û
  • hearing
    1. û°¢, û·Â 2. µè±â, ûÃë
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • screening
    °Ë»ö, ¼±º°
  • screening test
    ¼±º°°Ë»ç
  • absolute hearing
    Àý´ëÀ½°¨
  • air conduction hearing
    °ø±âÀü´Þµè±â, ±âµµÃ»·Â
  • audiometric hearing loss
    û·Â¼Ò½Ç
  • electric hearing aid
    Àü±âº¸Ã»±â
  • hearing acuity
    û·Â
  • hearing aid
    º¸Ã»±â
  • transistor hearing aid
    Æ®·£Áö½ºÅͺ¸Ã»±â
  • binaural hearing
    ¾çÂʱ͵è±â
  • binaural hearing effect
    µÎ±Íµè±âÈ¿°ú
  • bone conduction hearing
    »ÀÀüµµµè±â, °ñµµÃ»·Â
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • condensed milk conductive hearing loss
    ³óÃà¿ìÀ¯ÀüµµÃ»°¢¼Ò½Ç
  • conductive hearing loss
    Àüµµ³­Ã»
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody screening cells
    Ç×ü¼±º°Ç÷±¸
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • health screening
    °Ç°­Áø´Ü°Ë»ç, °Ç°­¼±º° °Ë»ç.
  • population screening
    Áý´Ü°ËÁø(̤ËÀ˧̤).
  • Frequency theory of hearing
    û°¢(ôéÊÆ)ÀÇ Áøµ¿¼ö(òÉÔÑâ¦) Çм³(ùÊàã)
  • Hearing
    û°¢(ôéÊÆ)
  • Hearing test
    û·ÂÅ×½ºÆ®
  • NIHL [=noise induced hearing loss]
    ¼ÒÀ½¼º ³­Ã»
  • absolute hearing
    Àý´ëÀ½°¨
  • functional hearing loss
    ±â´É(¼º) ³­Ã»
  • group hearing aid
    Áý´Üº¸Ã»±â
  • hearing =audition
    û·Â, û°¢
  • hearing =audition
    û°¢(ôéÊÆ), û·Â(ôéæ³)
  • hearing acuity
    û·Â
  • hearing aid
    º¸Ã»±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • screening coordinate recorder
    ÁÖ»ç½ÄÁÂÇ¥±â·Ï±â(ñËÞÛãÒñ¨øöÑÀÒÓÐï).
  • screening procedure
    ¼±º°ÀÛ¾÷
  • screening program
    Áý´Ü°ËÁø»ç¾÷(̤ËÀ˧̤Ë×Ëâ), À¯¼Ò°ßÀڹ߰߻ç¾÷.
  • screening test
    ¼±º°°Ë»ç
  • sun screening agent
    ž籤(¼±)Â÷´Ü<ºÀ¼â>Á¦, Àϱ¤Â÷´Ü<ºÀ¼â>Á¦, Â÷±¤Á¦
  • urine screening
    ¿ä¼±º°
  • epidemic diarrhea of newborn
    ½Å»ý¾Æ(ãæßæä®) À¯Ç༺ ¼³»ç.
  • epidemic diarrhea of newborn
    ½Å»ý¾Æ(ËàË×Ëâ) À¯Ç༺ ¼³»ç.
  • hemolytic disease of fetus/newborn
    žÆ/½Å»ý¾Æ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of newborn
    ½Å»ý¾Æ¿ëÇ÷¼º Áúȯ.
  • hemolytic disease of newborn
    ½Å»ý¾Æ ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of newborn
    ½Å»ý¾Æ¿ëÇ÷¼º Áúȯ.
  • hemorrhagic disease of newborn
    ½Å»ý¾ÆÃâÇ÷(¼º) Áúȯ.
  • idiopathic respiratory distress of newborn infant =IRDNI
    ½Å»ý¾ÆÆ¯¹ß¼º È£Èí°ï¶õÁõ.
  • jaundice in newborn
    ½Å»ý¾ÆÈ²´Þ(ãæßæä®üÜÓ¸).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PPHN Persistent Pulmonary Hypertension of the Newborn; ½Å»ý¾Æ Æóµ¿¸Æ °íÇ÷¾Ð Á¸¼ÓÁõ
  = PFC
TTN Transient Tachypnea of Newborn; ½Å»ý¾Æ Àϰú¼º ºóÈ£Èí
  = Wet Lung Disease; ºÎÁ¾ÆóÁõ
  ...
FTNB full-term newborn
HDN hemolytic disease of the newborn
HN head and neck; head nurse; hemagglutinin neuraminidase; hematemesis neonatorum; hemorrhage of newbor...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PPHN Persistent Pulmonary Hypertension of the Newborn
NB newborn
N.C.S. newborn calf serum
CHEST Chick Embrotoxicity Screening Test
CAST Children of Alcoholics Screening Test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hearing disturbance
    û·Â Àå¾Ö
    À½À» Á¦´ë·Î ´À³¢Áö ¸øÇÏ´Â »óÅÂ.
  • hearing organ
    û°¢ ±â°ü
    À½À» ´À³¢´Âµ¥ »ç¿ëµÇ´Â ±â°üÀ¸·Î external acoustic meatus¸¦ ºñ·ÔÇÏ¿© ear drum µîÀ» Æ÷ÇÔÇÑ´Ù.
  • monaural hearing
    ÀÏÀÌ Ã»°¢
  • sensorineural hearing loss
    °¨°¢ ½Å°æ¼º ³­Ã»
  • sensory hearing loss
    °¨°¢¼º ³­Ã»
    ¿Í¿ì
  • speech hearing test
    ¾îÀ½ û·Â °Ë»ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
drug screening Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
(12 Dec 1998)
drug screening assays, antitumour Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumour growth parameters in laboratory animals.
(12 Dec 1998)
familial screening Screening directed at close relatives of probands with diseases that may lie latent, as in age-dependent dominant traits, or that may involve risk to progeny, as X-linked traits.
(05 Mar 2000)
ABO haemolytic disease of the newborn Erythroblastosis foetalis due to maternal-foetal incompatibility with respect to an antigen of the ABO blood group; the foetus possesses A or B antigen which is lacking in the mother, and the mother produces immune antibody which causes haemolysis of foetal erythrocytes.
(05 Mar 2000)
bullous impetigo of newborn Usually, widely disseminated bullous lesions appearing soon after birth, caused by infection with Staphylococcus aureus.
Synonym: impetigo neonatorum, pemphigus gangrenosus.
(05 Mar 2000)
respiratory distress syndrome of the newborn A disease seen especially in premature neonates with respiratory distress; characterised postmortem by atelectasis and alveolar ducts lined by an eosinophilic membrane; also associated with reduced amounts of lung surfactant.
Synonym: hyaline membrane syndrome, respiratory distress syndrome of the newborn.
(05 Mar 2000)
pleural effusion in newborn <radiology> Chylothorax most common cause of large effusion, erythroblastosis foetalis, Turner syndrome, congestive heart failure, infantile polycystic kidneys, wet-lung disease, hypervolaemia (idiopathic or iatrogenic), oesophageal tear, enteric cyst, obstructed pulmonary veins
(12 Dec 1998)
congenital epulis of newborn A congenital benign nodular tumour of the alveolar ridge, of unknown histogenesis; histologically, it is composed of large cells with a granular cytoplasm similar to that of a granular cell tumour (myoblastoma).
(05 Mar 2000)
postnatal pit of the newborn It marks the site where the embryonic spinal cord attaches to the skin.
Synonym: postnatal pit of the newborn.
(05 Mar 2000)
haemolytic anaemia of newborn <haematology> A condition which develops in the foetus due to an incompatibility between the mother's blood type (RH factor) and the baby's. Maternal antibodies, which enter the foetal circulation during delivery attack the baby's red blood cells leading to haemolysis (rupture of the cells).
Symptoms include an infant with an enlarged liver and spleen, swelling, jaundice and anaemia.
(27 Sep 1997)
haemolytic disease of newborn <haematology> A condition which develops in the foetus due to an incompatibility between the mother's blood type (RH factor) and the baby's. Maternal antibodies, which enter the foetal circulation during delivery attack the baby's red blood cells leading to haemolysis (rupture of the cells).
Symptoms include an infant with an enlarged liver and spleen, swelling, jaundice and anaemia.
(27 Sep 1997)
haemolytic disease of the newborn Abnormal breakup of red blood cells in the foetus or newborn. This is usually due to antibodies made by the mother directed against the baby's red cells. It is typically caused by rh incompatibility, that is differences between the mother and baby uinvolving the rh blood group.
(12 Dec 1998)
haemorrhagic disease of newborn A self-limited haemorrhagic disorder of the first days of life, caused by a deficiency of the vitamin k-dependent blood coagulation factors II, vii, ix, and x.
(12 Dec 1998)
haemorrhagic disease of the newborn A syndrome characterised by spontaneous internal or external bleeding accompanied by hypoprothrombinaemia, slightly decreased platelets, and markedly elevated bleeding and clotting times, usually occurring between the third and sixth days of life and effectively treated with vitamin K.
(05 Mar 2000)
hyaline membrane disease of the newborn A disease seen especially in premature neonates with respiratory distress; characterised postmortem by atelectasis and alveolar ducts lined by an eosinophilic membrane; also associated with reduced amounts of lung surfactant.
Synonym: hyaline membrane syndrome, respiratory distress syndrome of the newborn.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á